Abstract
The use of bacterial extracts in Allergology are real facts; made from bacterial species, involving upper and lower airways and / or urinary tract infections. Bacterial antigens are obtained from suspensions of dead bacteria. Bacterial structures provide the main source of immuno-adjuvants, perhaps because they signal infection dangers, and it is no accident that incorporation of the "carrier" of the gene encoding a given immunogen can be so effective. And not only are bacterial lysates administered, bacterial toxins also come into play, which lose their toxicity and maintain their antigenicity, when treated they become toxoids, which stimulate the production of antibodies. The administration of endotoxins demonstrated an early but transitory increase in resistance to infections after their systematic administration. Viable germs and non-viable parts of microbial organisms are found in nature and are found in variable concentrations in both outdoor and indoor environments. These microbial substances are recognized by the innate immune system in the absence of infection and induce a powerful inflammatory response. Exposure to endotoxins, lipopolysaccharide fragments that surround the outer membrane of gram-negative bacteria, is particularly interesting. Endotoxins are in the environment and produce a wide spectrum of acute and chronic respiratory tract manifestations. However, there is evidence that early life exposure to environmental endotoxins can protect against allergy or asthma development.
References
Matricardi B, Bjorksten S, Bonini J, Bousquet R, Djukanovic S, Dreborg J. Wold EAACI Task Force 7, 2003
Infecciones. En: Weslwy Alexander J, Good RA. Principios de la inmunología clínica. Editors; Editorial REVERTÉ, S.A., 1980. p.203-13.
Finlay B, McFadden G. Anti-immunology: evasion of the host immune system by bacterial and viral pathogens. Cell [Internet]. 2009[citado nov. 2011];124(4):[aprox. 6 p.]. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/16497587?dopt=Abstract
Global strategy for asthma management and prevention. WHO/NHLBI workshop report. NIH, NHLBI, Publication no. 95-3659, 1995.
Malling HJ, Weeke B (eds). Immunotherapy. EAACI position paper. Allergy 1993;48(Suppl 14):9–45.
Bousquet J, Lockey RF, Malling HJ (editors). Allergen immunotherapy: therapeutic vaccines for allergic diseases. WHO position paper. Allergy 1998;53(Suppl 44):1–42.
Abbas AK, Lichtman AH, Pober JS (eds). Chapter sixteen. Immunity to Microbes. In: Cellular and Molecular Immunology. Philadelphia: WB Saunders, 1994:319-36.
Fainboim L, Satz ML(eds). Capítulo 1. Conceptos generales de inmunidad. En: Introducción a la Inmunología Humana. Buenos Aires, 1995:1-14.
Fainboim L, Satz ML(eds). Capítulo 11. Células efectoras de la respuesta inmune. En: Introducción a la Inmunología Humana . Buenos Aires, 1995:185-222.
Fainboim L, Satz ML(eds). Capítulo 13. Inmunidad frente a agentes microbianos. En: Introducción a la Inmunología Humana. Buenos Aires, 1995:233-48.
Young D. Vaccine Challenges: Tuberculosis. In: Mérieux Foundation (eds.). Proceedings of the Advanced Vaccinology Course. Session VIII Challenges for Control of Specific Diseases. France:Annecy 2000.
Poolman J. Neisseria meningitidis B. Current Medical Need and Rationales for Prevention of Meningitis and Meningococcemia Via Vaccination. In: Mérieux Foundation (eds.). Proceedings of the Advanced Vaccinology Course. Session VIII Challenges for Control
Rolando F. Ochoa A, Teresita A. Leiva Sánchez. Mecanismos de defensa frente a las infecciones bacterianas. Microbiología y Parasitología Médicas; 2009.
Sanz Larruga ML. Martines Quesada J, Escudero R, GArcia Figueroa BE. Anticuerpos. Inmunoquímica. Síntesis y regulación de la IgE. En: Tratado de Alergología SEICAC, 2010 Cap 2. p.45.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2021 Daniel Ramón Gutierrez Rodriguez